Active — Not RecruitingNot Applicable

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

United States20 participantsStarted 2024-12-11

Plain-language summary

The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Participants undergoing regular treatment for their skin cancer will provide blood samples.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years. * Participants must meet at least one of the following criteria: * Finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. Non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. * A confirmed diagnosis of melanoma or non-melanoma skin cancer. Exclusion Criteria: * Vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \&lt;18), and UW employees that report to the investigator(s) or to study team members. * Not suitable for study participation due to other reasons at the discretion of the investigators.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in tumor-derived exosomes and progression free survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor cells and progression free survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor DNA and progression free survival

Timeframe: Baseline to progression, up to 3 years

Change in tumor-derived exosomes and overall survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor cells and overall survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor DNA and overall survival

Timeframe: Baseline to progression, up to 3 years

Change in tumor-derived exosomes and treatment response

Timeframe: Baseline to progression, up to 3 years

Trial details

NCT IDNCT06608511

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Skin Cancer trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in tumor-derived exosomes and progression free survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor cells and progression free survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor DNA and progression free survival

Timeframe: Baseline to progression, up to 3 years

Change in tumor-derived exosomes and overall survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor cells and overall survival

Timeframe: Baseline to progression, up to 3 years

Change in circulating tumor DNA and overall survival

Timeframe: Baseline to progression, up to 3 years

Change in tumor-derived exosomes and treatment response

Timeframe: Baseline to progression, up to 3 years